Trading involves risk
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
REVOLUTION Medicines Inc
Open
SectorHealthcare
58 -0.19
Overview
Share price change
24h
Min
57.04
Max
58.45
Income | -34M -248M |
|---|---|
Profit margin | -74.379 |
Employees | 700 |
EBITDA | -24M -261M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +30.77% upside |
Market Cap | 3.9B 11B |
|---|---|
Previous open | 58.19 |
Previous close | 58 |
News Sentiment
By Acuity
50%
50%
154 / 373 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
REVOLUTION Medicines Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
REVOLUTION Medicines Inc Forecast
Price Target
By TipRanks
30.77% upside
12 Months Forecast
Average 76.07 USD 30.77%
High 90 USD
Low 66 USD
Based on 17 Wall Street analysts offering 12 month price targets forREVOLUTION Medicines Inc - Dist in the last 3 months.
Sentiment
By Acuity
154 / 373 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About REVOLUTION Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Live chat